文献速递

系统性硬化症恶性肿瘤关联的临床与自身抗体特征:系统综述与荟萃分析

Clinical and autoantibody associations with malignancy in systemic sclerosis: a systematic review and meta-analysis
RSS 订阅 · PubMed 高证据 · 肺动脉高压 · 2026-07-02

结果显示,合并恶性肿瘤与发病年龄较大、男性、吸烟、肺动脉高压、间质性肺病、dcSSc、anti-RNAPIII 阳性及 ANA 阴性相关,ACA 阳性呈负相关;作者据此提出按风险分层的恶性肿瘤监测策略,而非统一筛查。

要点

  • 合并恶性肿瘤的 SSc 患者发病年龄更大(MD +4.01,95% CI 1.24-6.78)。
  • 男性、吸烟、肺动脉高压、anti-RNAPIII 阳性与恶性肿瘤的关联在高研究质量敏感性分析中保持显著。
  • 肺癌与男性(OR 2.72)、吸烟(OR 2.38)、anti-topo I(OR 2.45)及 ILD(OR 2.98)相关,ACA 呈负相关(OR 0.32)。

核心结论

  • SSc 中的恶性肿瘤关联受临床表型与自身抗体谱影响,建议采用风险分层的监测策略,而非统一筛查。

主要发现

  • 合并恶性肿瘤者发生 SSc 的年龄更大(MD +4.01,95% CI 1.24-6.78)。
  • 恶性肿瘤关联显著的因素包括男性(OR 1.36)、吸烟(OR 1.27)、肺动脉高压(OR 1.32)、间质性肺病(OR 1.41)、dcSSc(OR 1.14)、anti-RNAPIII 阳性(OR 1.79)、ANA 阴性(OR 1.39),ACA 阳性(OR 0.83)呈负相关。
  • 高质量研究敏感性分析中,男性、吸烟、肺动脉高压与 anti-RNAPIII 仍显著。
  • 肺癌与男性(OR 2.72)、吸烟(OR 2.38)、anti-topo I(OR 2.45)、ILD(OR 2.98)正相关,与 ACA 负相关(OR 0.32)。
  • anti-RNAPIII 与乳腺癌(OR 2.17)及早期/同期恶性肿瘤(OR 2.85)相关,指端溃疡与后期恶性肿瘤发生相关(OR 0.39)。

关键数值与推荐

  • 男性 OR 1.36、吸烟 OR 1.27、肺动脉高压 OR 1.32、ILD OR 1.41、dcSSc OR 1.14。
  • anti-RNAPIII 阳性 OR 1.79、ACA 阳性 OR 0.83、ANA 阴性 OR 1.39。
  • 肺癌亚组:男性 OR 2.72、吸烟 OR 2.38、anti-topo I OR 2.45、ILD OR 2.98、ACA OR 0.32。
  • anti-RNAPIII 与乳腺癌 OR 2.17、早期/同期恶性肿瘤 OR 2.85;指端溃疡与后期恶性肿瘤 OR 0.39。

临床怎么用

  • 对 SSc 患者按临床表型与自身抗体谱进行恶性肿瘤风险分层,而非一律统一筛查。
  • 男性、吸烟、合并肺动脉高压或 ILD、anti-RNAPIII 阳性的 SSc 患者可考虑加强恶性肿瘤监测。
  • anti-topo I 阳性或合并 ILD 者需关注肺癌风险,ACA 阳性者的恶性肿瘤风险相对较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rheumatology (Oxford). 2026 Sep 1;65(9):keag356. doi: 10.1093/rheumatology/keag356. ABSTRACT OBJECTIVE: This meta-analysis examined factors associated with malignancy in SSc. METHODS: A systematic search of the Embase, MEDLINE and Cochrane Library databases was conducted from inception to 7 December 2024. Case-control and cohort studies reporting associations with malignancy in SSc were included. Random-effects meta-analyses were performed to pool study results. Mean differences (MDs) for age and odds ratios (ORs) for binary outcomes using frequency counts were calculated. Study quality was assessed using Newcastle-Ottawa Scale. RESULTS: Thirty-five studies comprising 27 624 SSc patients were analysed. Patients with malignancy developed SSc at an older age (MD +4.01, 95% CI 1.24-6.78). Significant associations for malignancy included male gender (OR 1.36), smoking (OR 1.27), pulmonary hypertension (PH, OR 1.32), interstitial lung disease (ILD; OR 1.41), dcSSc (OR 1.14), positive anti-RNAPIII (OR 1.79) and ACA (OR 0.83), and negative ANA (OR 1.39). In sensitivity analyses of high-quality studies, male gender, smoking, PH and anti-RNAPIII remained significant. Subgroup analyses by malignancy types and development in relation to SSc diagnosis revealed positive associations of lung malignancy with male gender (OR 2.72), smoking (OR 2.38), anti-topo I (OR 2.45) and ILD (OR 2.98), while ACA was inversely associated (OR 0.32). Anti-RNAPIII was associated with breast malignancy (OR 2.17) and early/concurrent malignancy (OR 2.85), and digital ulceration (OR 0.39) with later malignancy development. CONCLUSION: Malignancy association in SSc is influenced by clinical phenotype and autoantibody profile. Our findings suggest a risk-stratified approach to malignancy surveillance rather than uniform screening. PMID: 42391056 | DOI: 10.1093/rheumatology/keag356

来源:PubMed 高证据 · 肺动脉高压,查看原文。版权归原作者所有。

引用

  1. PubMed 高证据 · 肺动脉高压:Clinical and autoantibody associations with malignancy in systemic sclerosis: a systematic review and meta-analysis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。